GET DAILY SIGNALSNeuronetics (STIM) Shares Decline -24% Over 30 Days Following Dilutive Offering
Key Takeaways
- Neuronetics (STIM) shares fell roughly 24% over the past 30 days, from about $2.13 on October 12, 2026, to $1.62 at the November 11 close.
- The decline was driven primarily by a dilutive $30 million underwritten public offering priced at $1.60 per share, alongside balance-sheet and going-concern concerns tied to the company's Perceptive credit facility.
- The sell-off followed a strong third-quarter report on November 4, in which revenue rose 12.5% to $42.0 million, gross margin reached 52.2%, and adjusted EBITDA turned positive at $1.9 million.
- On November 5, Neuronetics amended its credit agreement through the Perceptive Sixth Amendment, designed to reduce revenue covenants but conditional on a prepayment of at least $15 million and expiring if conditions are not met by November 30, 2026.
- Over the past quarter, the stock has fallen roughly 49% from about $3.19 in mid-August, reflecting sustained cash-burn and capital-structure pressures despite improving operating results.
- For additional data and analyst context, explore Neuronetics' Price Targets, Earnings, and Forecast pages.
- Discover top-performing trading strategies on Tickeron's Trending AI Robots page.
Neuronetics (STIM) Company Overview and Market Position
Neuronetics, Inc. is a medical technology company focused on interventional mental health. Its flagship NeuroStar Advanced Therapy system uses transcranial magnetic stimulation (TMS) to treat major depressive disorder (MDD) in adults, and the device holds additional FDA clearances for obsessive-compulsive disorder, anxious depression, and adolescent depression in patients aged 15-21. Through its Greenbrook TMS network, the company also operates one of the largest interventional psychiatry clinic networks in the United States, offering TMS and SPRAVATO (esketamine) therapy directly to patients. Investors follow STIM for its position in the growing non-drug mental-health treatment market, its recurring treatment-session and capital-equipment revenue streams, and its progress toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Neuronetics (STIM) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, STIM shares declined from $2.13 at the October 12 close to $1.62 on November 11, a drop of about 24%. Much of that decline occurred in a single session, when the stock fell 19.4% on November 11 after the company priced its equity offering.
The broader quarterly trend has been steeper. From roughly $3.19 in mid-August, the stock has fallen about 49%. The shares rallied sharply in mid-August before trending lower through September and October, then accelerated downward in early November as financing and balance-sheet announcements outweighed improving operating fundamentals. From what I see, this pattern highlights how capital-structure issues can overshadow operational gains in the near term.
What Drove STIM Stock Price in the Last 30 Days
The 30-day decline was defined by a financing event rather than an operating setback. On November 4, Neuronetics reported third-quarter results that beat expectations, with total revenue of $42.0 million, Greenbrook revenue up 20.1% to $26.2 million, a gross margin of 52.2%, and adjusted EBITDA of $1.9 million. The shares spiked intraday in response before giving back those gains. I pulled the earnings details from Tickeron’s resources to confirm the numbers aligned with expectations.
The reversal followed two developments. On November 5, the company disclosed the Perceptive Sixth Amendment to its credit agreement, which would reduce certain revenue covenants but requires a prepayment of at least $15 million and terminates automatically if conditions are not met by November 30, 2026. Management stated that satisfying the amendment would resolve the going-concern risk flagged in recent 10-Q filings.
On November 10, Neuronetics announced a proposed public offering, and on November 11 it priced a $30 million underwritten offering of 18.75 million common shares at $1.60 per share, below the prior closing price. The dilution, combined with the disclosure that proceeds would partly repay the Perceptive term loan, drove the sharp single-day sell-off.
What Drove STIM Stock Performance Over the Last Quarter
The quarterly decline reflects a longer-running tension between improving operations and a constrained balance sheet. During the quarter, Neuronetics submitted an FDA 510(k) application for an accelerated TMS protocol, announced a distribution agreement with Wave Neuro to pursue a PTSD indication, and launched a first-of-its-kind integration of its TrakStar practice-management platform with AdvancedMD's EHR system. The company also began deploying Skypoint, an AI-enabled coding tool, to improve collections.
Despite these operational advances and a return to positive adjusted EBITDA, investors have remained focused on dilution, cash burn, and the company's credit-facility covenants. The November equity raise, while intended to strengthen the balance sheet, intensified concerns about shareholder dilution and reinforced the downward trend that had been building since the stock's mid-August peak. In my view, this underscores the importance of monitoring both clinical progress and financing needs closely.
STIM Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor the closing of the $30 million offering, expected on or about November 12, 2026, and whether the conditions of the Perceptive Sixth Amendment are satisfied by the November 30 deadline. Further items to watch include the company's full-year 2026 guidance (revenue of $160 million to $164 million and gross margin of 49% to 50%), progress on the accelerated TMS 510(k) submission and the Wave Neuro PTSD integration, and the rollout of the AdvancedMD EHR integration. Continued execution on Greenbrook revenue-cycle management and the shift toward capital-equipment sales will also influence sentiment, along with any further financing or covenant actions. I’m watching this closely as the November 30 deadline approaches.
Exploring AI Tools for Market Analysis
One resource I turn to regularly for systematic strategies is Tickeron’s AI Trading Bots. It offers access to hundreds of automated approaches across thousands of tickers, with a focused view of top-performing options that can complement individual research on names like STIM. The platform allows users to review quantitative, data-driven methods by timeframe and performance metrics, providing another layer of insight alongside fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
STIM in +31.31% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where STIM advanced for three days, in 227 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STIM's RSI Oscillator exited the oversold zone, 34 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
STIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STIM as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for STIM turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
STIM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for STIM entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.178) is normal, around the industry mean (4.142). P/E Ratio (-5.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.250) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. STIM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of non-invasive therapies for psychiatric and neurological disorders
Industry MedicalNursingServices
Advertisement